6th Aug 2015 10:55
LONDON (Alliance News) - GW Pharmaceuticals PLC said Thursday it has received a fast track designation from the US Food and Drug Administration for its intravenous form of cannabidiol for the treatment of Neonatal Hypoxic-Ischemic Encephalopathy.
Additionally, the European Medicines Agency has also granted the same product with an orphan drug designation to treat perinatal asphyxia.
Perinatal asphyxia is an alternate term describing the same condition, and GW Pharmaceuticals has already got an orphan drug designation from the FDA for this condition.
Both conditions are forms of an acute or sub-acute brain injury due asphyxia caused during the birth process, and resulting from deprivation of oxygen during birth.
Shares in GW Pharmaceuticals were up 2.0% at 623.62 pence Thursday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
GWP.L